Comparable stake leader
Alumni Capital LP
SEC ownership of RedHill Biopharma Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001553846.
Disclosed value leader
Alumni Capital LP
Comparable rows
15/25
Latest evidence
10 Jul 2026
- Public ticker
- RDHL on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alumni Capital LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
15 of 25
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alumni Capital LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
10 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001553846
- Issuer location
- Tel Aviv, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RedHill Biopharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alumni Capital LP
Disclosed value leader
Alumni Capital LP
Comparable rows
15/25
Latest evidence
10 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
10 rows are not safely comparable across share classes.
13D/G row: Alumni Capital LP
Showing 1-8 of 25 holder rows.
Quick read
Alumni Capital LP leads the comparable SEC ownership view at 10%.
15 of 25 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alumni Capital LP's linked filing trail.
Comparable ownership
Top 5
Alumni Capital LP
10%
YA II PN, Ltd.
9.9%
Yorkville Advisors Global, LP
2.4%
GAGNON SECURITIES LLC
1.7%
CITADEL ADVISORS LLC
1.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 25 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alumni Capital LP |
13D/G
|
10%
|
$801,687
369,373 shares
|
$0 | 20 Jun 2025 |
| YA II PN, Ltd. |
13D/G
|
9.9%
|
$559,595
508,723 shares
|
$0 | 19 Dec 2025 |
| Yorkville Advisors Global, LP |
13F
Company
|
2.4%
|
$106,681
122,131 shares
|
— | 30 Jun 2026 |
| GAGNON SECURITIES LLC |
13F
Company
|
1.7%
|
$74,702
88,405 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.3%
|
$55,196
65,321 shares
|
— | 30 Jun 2026 |
| RHUMBLINE ADVISERS |
13F
Company
|
0.27%
|
$11,620
13,755 shares
|
— | 30 Jun 2026 |
| Lido Advisors, LLC |
13F
Company
|
0.21%
|
$9,303
11,009 shares
|
— | 30 Jun 2026 |
| GAMMA Investing LLC |
13F
Company
|
0.14%
|
$5,879
6,957 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to RedHill Biopharma Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Dror Ben-Asher
Net 12M change
$0
Latest report
10 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dror Ben-Asher | Chief Executive Officer, Director | Mixed | 18 Mar 2026 | |||
| Shmuel Cabilly | Director | Mixed | 18 Mar 2026 | |||
| Adi Frish | Chief Corp & BD Officer | Mixed | 18 Mar 2026 | |||
| Guy Joel Goldberg | Chief Business Officer | Mixed | 18 Mar 2026 | |||
| Razi Ingber | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Roni Mamluk | Director | Mixed | 18 Mar 2026 | |||
| Gilead Raday | Chief Operating Officer | Mixed | 10 Jul 2026 | |||
| Kenneth Reed | Director | Mixed | 18 Mar 2026 | |||
| Rick D. Scruggs | Chief Commercial Officer, Director | Mixed | 18 Mar 2026 | |||
| Ofer Tsimchi | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for RedHill Biopharma Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Raday | RDHL | Ordinary Shares | Sale | -6.07% | -14,130,000 | 218,780,000 | 10 Jul 2026 | Direct | ||
| Gilead Raday | RDHL | American Depositary Shares | Options Exercise | 37% | 28,150,000 | 104,130,000 | 10 Jul 2026 | Direct | ||
| Gilead Raday | RDHL | Ordinary Shares | Sale | -5.69% | -15,740,000 | 261,060,000 | 06 Apr 2026 | Direct | ||
| Gilead Raday | RDHL | American Depositary Shares | Options Exercise | 67.8% | 30,780,000 | 76,150,000 | 06 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.